glp 1 作動 薬 セマグルチドやその他の GLP-1作動薬の重篤な麻酔リスクは十分に認識されていないのか?麻酔患者の固形胃内容物残留に関する症例報告 GLP-1受容体作動薬（マンジャロ）ダイエットについて | 鳥取のよろずクリニック〈美容診療〉

Hepatic enzyme-inducing ASMs reduce levels of VK-dependent proteins, critical for vascular and neuronal health, while increasing bleeding risk in patients receiving VK antagonists

Application of firm, even pressure causes the autoinjector to fire, pushing its needle into the muscle with injection of its fluid contents

10.1210/me.2012-1004 133 YaoH.ZhangA.LiD.WuY.WangC.-Z.WanJ.-Y.et al (2024)

Best for: Injection-averse patients, those new to GLP-1 therapy GLP-1 Medications for Weight Loss While GLP-1 drugs were originally designed for diabetes, weight loss emerged as a major secondary effect in clinical trials and for some agents, the primary FDA-approved indication

The modification of cysteine residues in proteins is critically important for the design of novel types of pharmacological agents